Aclarion, Inc. (ACON)
NASDAQ: ACON · Real-Time Price · USD
12.12
+11.60 (2,221.84%)
At close: Mar 28, 2025, 4:00 PM
11.45
-0.67 (-5.53%)
After-hours: Mar 28, 2025, 7:56 PM EDT
Aclarion Revenue
Aclarion had revenue of $14.41K in the quarter ending September 30, 2024, a decrease of -24.43%. This brings the company's revenue in the last twelve months to $49.29K, down -41.41% year-over-year. In the year 2023, Aclarion had annual revenue of $75.40K with 24.75% growth.
Revenue (ttm)
$49.29K
Revenue Growth
-41.41%
P/S Ratio
9.25
Revenue / Employee
$8,215
Employees
6
Market Cap
456.02K
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 75.40K | 14.96K | 24.75% |
Dec 31, 2022 | 60.44K | 152.00 | 0.25% |
Dec 31, 2021 | 60.29K | 11.64K | 23.93% |
Dec 31, 2020 | 48.65K | 21.76K | 80.88% |
Dec 31, 2019 | 26.90K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ACON News
- 17 days ago - Aclarion Provides Shareholder Update - GlobeNewsWire
- 24 days ago - Aclarion Announces Expansion Plans with RadNet Affiliates in New York and New Jersey - GlobeNewsWire
- 27 days ago - Aclarion Announces First Commercial Agreement with Scripps Health - GlobeNewsWire
- 5 weeks ago - Aclarion to Showcase Groundbreaking NOCISCAN Technology at the 2025 Spine Summit - GlobeNewsWire
- 6 weeks ago - Aclarion Receives US Patent to Protect Expanded Applications of Magnetic Resonance Spectroscopy (MRS) Data Processing to Identify Pain and Infection Biomarkers Throughout the Body - GlobeNewsWire
- 7 weeks ago - Aclarion Announces Northwestern Medicine as First CLARITY Trial Site - GlobeNewsWire
- 7 weeks ago - Aclarion Announces CLARITY Trial for Nociscan Now Fully Funded - GlobeNewsWire
- 4 months ago - Aclarion Announces Nociscan Featured in RSNA Edition of Siemens MAGNETOM Flash - GlobeNewsWire